UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Company profile
Ticker
UCBJF, UCBJY
Exchange
Website
CEO
Jean-Christophe Tellier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
980366580
UCBJF stock data
Latest filings (excl ownership)
SC TO-T/A
Third party tender offer statement (amended)
7 Mar 22
SC TO-T/A
Third party tender offer statement (amended)
4 Mar 22
SC TO-T/A
Third party tender offer statement (amended)
28 Feb 22
SC TO-T
Third party tender offer statement
1 Feb 22
SC TO-C
Information about tender offer
19 Jan 22
F-6EF
Automatic registration for ADRs (foreign)
22 Nov 19
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
29 Sep 17
D
$787.63K in equity, sold $787.63K, 131 investors
13 May 15
F-6EF
Automatic registration for ADRs (foreign)
31 Oct 14
F-6EF
Automatic registration for ADRs (foreign)
17 Jun 14
Latest ownership filings
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
10 Nov 22
SC 13G/A
Dermira, Inc.
17 Mar 17
SC 13G
Dermira, Inc.
21 Dec 16
SC 13G
LANNETT CO INC
3 Dec 15
144/A
CYTEC INDUSTRIES INC/DE/
8 Nov 06
144/A
CYTEC INDUSTRIES INC/DE/
31 Oct 06
144
CYTEC INDUSTRIES INC/DE/
17 Oct 06
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|